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Context: Experimentally controlled studies of estrogenic regulation of lipid measures and in-
flammatory cytokines in men are rare.
Objective: To delineate the effect of estradiol (E2) on lipids and inflammatory markers.
Design: This was a placebo-controlled, single-masked, prospectively randomized study comprising
experimentally degarelix-downregulated healthymen [n = 74; age 65 years (range, 57 to 77)] assigned to
four treatment groups: (1) IM saline and oral placebo; (2) IM testosterone and oral placebo; (3) IM
testosterone and oral anastrozole (aromatase inhibitor); and (4) IM testosterone, oral anastrozole, and
transdermal E2 for 22 (61) days.
Results:Mean mass spectrometry–quantified serum E2 concentrations ranged from 1.2 to 82 pg/mL in
the four treatment groups. E2 extremes did not alter total cholesterol, triglyceride, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol (HDL-C) , non–HDL-C, apolipo-
protein B, lipoprotein (a), IL-6, or high-sensitivity C-reactive protein (hsCRP) concentrations. Higher
E2 concentrations elevated both sex hormone-binding globulin and prolactin as positive controls. LDL
cholesterol, adiponectin, and leptin were higher in hypogonadal subjects without testosterone or
E2 addback (P = 0.018, 0.039, and 0.023, respectively). Abdominal visceral fat area by CT (independent
variable) correlated negatively with HDL-C (P = 0.017), and positively with triglycerides (P = 0.004),
hsCRP (P = 0.005), and leptin (P , 0.0001).
Conclusion: In this placebo-controlled prospectively randomized study, wide variations in circulating
E2 did not influence lipid measures and inflammatory markers when testosterone concentrations were
controlled experimentally. However, medically induced central hypogonadism in older men was ac-
companied by increased LDL cholesterol and metabolic cytokines, adiponectin and leptin. Abdominal
visceral fat correlated strongly and positively with triglycerides, hsCRP, and leptin, but negatively
with HDL.
Copyright © 2018 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Sex steroids are used extensively in estrogen treatment of menopausal symptoms, androgen
supplementation in men with low serum testosterone (T) levels, and androgen or estrogen
administration to transsexual patients [1–4]. Clinical concerns are potential cardiovascular
complications (myocardial infarction and cerebrovascular accidents), venous thromboses,
Abbreviations: ApoB, Apolipoprotein B; BMI, body mass index; CV, coefficient of variation; E2, estradiol; HDL-C, high-density li-
poprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a);
SHBG, sex hormone–binding globulin; T, testosterone; TC, total cholesterol; TG, triglyceride.
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and hormone-related cancers (breast, uterine, and prostatic) [5–7]. Investigation of the lipid
spectrum is one tool for assessing the safety of hormone treatment. Many studies have been
published on side effects of estrogen replacement in menopausal women, but less attention
has been devoted to potential drawbacks of estrogen repletion or deprivation in men. To
assess direct effects of sex steroids on lipid profiles, short-term studies are required, before
any substantial change in body composition occurs [7–9]. Nonetheless, many clinical sex-
hormone treatment studies are focused on long-term results [10–12]. In women, the choice
of a particular estrogen, its dose and route of administration, and concomitant use of pro-
gestin with more or less intrinsic androgenic effects can confound the interpretation of
metabolic results [13].
The degree to which estrogen regulates lipid or metabolic outcomes in men is unclear [7,
14–16]. Prior investigations have been handicapped by pathological and/or pharmacologic
settings and interventions, such as (diabetic) hypogonadism or surgical castration, high-dose
estrogen or human chorionic gonadotropin administration or mixed antiestrogen/partial
estrogen agonist treatment [5, 9, 15–19]. In most models, there are profound concurrent
changes in T availability, thus confounding interpretation of any estrogen effect per se. Under
such circumstances, low estrogen milieus tend to result in lower high-density lipoprotein
(HDL) concentrations, and conversely for high-estrogen milieus. Moreover, as suggested by
others, longer term interventions also alter body composition, typically lowering HDL
whenever abdominal visceral fat increases as under prolonged T deprivation [8, 20].
Although estrogen administration is a straightforward procedure for the assessment
of estrogen effects on the lipid profile in women, this is not the case for men. A major
confounding action of administered estrogen in men is downregulation of the gonadotropic
axis, resulting in decreased T production. Methods for increasing T in older men are more
complicated. Treatment with aromatase blockers causes T levels to increase and estradiol
(E2) levels to decrease, whereas exogenously administering T elevates not only T but also E2
concentrations [21]. Thus, for valid mechanistic studies of estrogen action per se, both T and
E2 levels must be controlled experimentally. This goal was accomplished here rapidly and
precisely by: (1) downregulation of the gonadotropic axis using a potent and selective GnRH
antagonist; (2) concomitant addback of placebo or T; (3) treatment with placebo or an aro-
matase inhibitor to decrease endogenously generated E2 from administered T; and (4) ad-
ministration of E2 along with the aromatase inhibitor and T in a clamp model [22]. This
fourfold strategy allowed us to investigate the effects of E2 under experimentally controlled T
levels. The purpose of this explorative study was to evaluate potential short-term effects of
sex steroids (especially E2) under controlled (T-clamped) conditions on lipids and selective
inflammation markers in 74 healthy older men.
1. Material and Methods
The study was designed to address whether E2 levels at fixed T availability affect lipid
concentrations and inflammatory markers measured in fasting blood obtained after 3 weeks
of the endocrine clamp.
A. Subjects
Seventy-four healthy, ambulatory, community-dwelling older men [mean age, 65 years
(range, 57 to 77)] participated in the overnight clinical unit–based study. The mean body
mass index (BMI) was 26.9 kg/m2 (range, 20 to 36). Volunteers were recruited by newspaper
advertisements, local posters, the Clinical Trials Center Web page, and community (general
and minority) bulletin boards. In this single-blind, prospectively randomized, placebo-
controlled study, all qualifying volunteers underwent gonadotropin downregulation
using the GnRH antagonist, degarelix (Ferring Pharmaceuticals, NY). The primary ran-
domization was to IM T vs IM saline, and transdermal E2 vs no E2, and oral placebo vs
anastrozole, an aromatase inhibitor (AstraZeneca Pharmaceuticals, Wilmington, DE). Thereby,
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the sex-hormone clamp comprised: (1) degarelix 80 mg (given as two subcutaneous injections of
40 mg) once (called day 1) (Ferring Pharmaceuticals, Parsippany, NY); (2) T enanthate or
T cypionate (Cardinal Health, Hudson,WI) 100mg or placebo IM given on day 1 and repeated
on days 8 and 15, range6 1 day; (3) oral placebo or anastrozole (AstraZeneca Pharmaceuticals,
Wilmington, DE) 2.0 mg once daily for 23 days; and (4) no patch or an E2 patch calibrated to
deliver 0.05 mg/d E2 transdermally (Novartis, Morris Plains, NJ) beginning on day 1 and
changed every 3 days through day 22. Statistical comparison was among the four resulting
groups: (1) degarelix/T/placebo/no patch; (2), degarelix/T/anastrozole/no patch; (3) degarelix/T/
anastrozole/E2 patch; and (4) degarelix/placebo/placebo/no patch.
Individuals arrived in the clinical research unit at or before 6:00 PM to permit placement of
bilateral forearm IV catheters for overnight fasting and blood sampling. A blood sample was
obtained at 8:00 AM for sex-hormone, lipids, inflammatory markers, and peptide measure-
ments. The study was embedded in a protocol in which the influence of sex steroids on
nocturnal GH secretion and the effect of GHRH onGH response were assessed (unpublished).
Ambulation was allowed to the lavatory. The volunteer was allowed to sleep. To reduce
nutritional confounds, subjects were given a prescribed meal to ingest at 6:00 PM on the
evening before. Men received a standardized 10 kcal/kg meal (vegetarian or nonvegetarian)
with a macronutrient composition of 20% protein, 50% carbohydrate, and 30% fat. Partic-
ipants then remained fasting for 12 hours overnight (except for allowable intake of noncaloric
and noncaffeinated liquids).
The protocol was approved by Mayo Institutional Review Board. Witnessed voluntary
written informed consent was obtained before study enrollment. A complete medical history,
physical examination, and screening tests of hematological, renal, hepatic, metabolic, and
endocrine function were normal. Subjects underwent a single-slice CT of the abdomen, level
L3-L4, as an exploratory test of the impact of relative visceral adiposity on lipid responses.
B. Exclusion Criteria
Exclusion criteria were acute or chronic systemic diseases, HIV positivity by medical history,
anemia, endocrine disorders (except hypothyroid subjects who were biochemically euthyroid
on replacement), psychiatric illness, alcohol or drug abuse, deep venous or arterial throm-
boses, cancer of any type (except localized basal or squamous cell cancer of the skin treated
surgically without recurrence), recent use (within 6 weeks) of anabolic steroids or gluco-
corticoids, history of stroke, myocardial infarction or angina, allergy to sex steroids used in
the study; substantial recent weight change (loss/gain of $6 lb over 6 weeks), transmeridian
travel (exceeding 3 time zones within the preceding 3 weeks), current or recent night shift
work, systemic drugs, abnormal renal, hepatic or hematologic function, concomitant sex-
hormone replacement, and unwillingness to provide written informed consent.
C. Assays
Total cholesterol (TC), triglycerides (TG), andHDL cholesterol (HDL-C) weremeasured using
the Roche Cobas c311 Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN) with
interassay coefficients of variation (CV) of 2.2%, 0.8%, and 0.6% at 249, 178, and 51 mg/dL,
respectively. Low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald
equation. Apolipoprotein B (ApoB) was measured immunoturbimetrically on the Hitachi
Chemistry Analyzer using the DiaSorin ApoB SPQ II Reagent Set (DiaSorin Inc., Stillwater,
MN) with an interassay CV of 4% at 94 mg/dL. Lipoprotein (a) [Lp(a)] was measured by a
turbidimetric immunoassay on the Roche Cobas c311 Chemistry Analyzer. The interassay
CVwas 4.3% at 21mg/dL. Interleukin-6 wasmeasured by a high-sensitivity two-site enzyme-
linked immunoassay from R&D Systems (Minneapolis, MN). The interassay CV was 3.6% at
3.88 pg/mL. Leptin and adiponectin were measured by specific immunoassays (Linco Re-
search, Inc., St. Louis, MO). The interassay CVs were 11% and 4.7% at 20.4 ng/mL and
29.9 ng/mL, respectively. High-sensitivity C-reactive protein (hsCRP) was measured by a
884 | Journal of the Endocrine Society | doi: 10.1210/js.2018-00141
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/article-abstract/2/8/882/5046520 by Leiden U
niversity / LU
M
C
 user on 15 August 2019
high-sensitivity immunoturbimetric assay on the Roche Cobas c311 Chemistry Analyzer. The
interassay CV was 1.7% at 0.17 mg/dL. E2 and total T were measured using liquid
chromatography-tandem mass spectrometry (Agilent Technologies, Inc., Santa Clara, CA).
Intraassay CVs were: E2, 10.8% at 0.29 pg/mL and 5.1% at 32 pg/mL; and T, 8.9% at 0.69 ng/
dL, 4.0% at 45 ng/dL, and 3.5% at 841 ng/dL. Sex hormone–binding globulin (SHBG), IGF-I,
and IGFBP3 were quantified by solid-phase chemiluminescent assay on the Siemens
Immulite 2000 Automated Immunoassay System (Siemens Health Care Diagnostics,
Deerfield, IL). Intraassay CV for SHBG was 4.0% at 5.4 nmol/L and 5.9% at 74 nmol/L; for
IGF-I, 4.9% at 37 mg/L and 5% at 225 mg/L; and for IGFBP3, 4% and 3.9% at 1.0 and 4.3 mg/L.
IGFBP1 was determined by a two-site immunoradiometric assay (Diagnostic Systems
Laboratories, Webster, TX). Interassay CVs were 10.2% at 0.49 mg/L and 6.7% at 4.5 mg/L.
The interassay CV was 1.7% at 0.17 mg/dL. Insulin was measured by a two-site immu-
noenzymatic sandwich assay on the Roche e411 (Roche Diagnostics). Intraassay CVs were
3.3%, 2.8%, and 2.5% at 18, 61, and 172mU/L. Prolactin, FSH, and LHweremeasured by two-
site chemiluminescent sandwich immunoassays on a DXL 800 automated immunoassay
system (Beckman Instruments, Chaska, MN). Intraassay CVs for prolactin were 3.7%, 2.1%,
and 4.8% at 6.1, 16.4, and 34.5 mg/L; for FSH, 3.6%, 3.2%, and 4.7% at 6.5, 16.7, and 58.0 IU/L;
and for LH, 9.3%, 6.0%, and 6.0% at 1.4, 15.6, and 48.8 IU/L, respectively.
D. Statistics
Data were analyzed by one-way ANOVA for the four randomly assigned treatment groups. In
case of nonnormal distribution, the Kruskal-Wallis nonparametric ANOVA test was used.
This was followed by the Dwass-Steel-Critchlow test for pairwise comparisons. Linear re-
gression analysis was applied to identify concentration-dependent effects of T and/or E2, and
effects of abdominal visceral fat. The statistical power of this study was 80% based upon a
change of 20% of mean lipid concentrations with a standard deviation of 20% when studying
12 to 15 subjects in each group.
Calculations were performed with Systat 13 (Systat Software, Inc., San Jose, CA). P, 0.05
was construed as significant for the overall study.
2. Results
Demographic and anthropomorphic data of the volunteers are presented in Table 1. Sta-
tistically, the four subject groups were balanced before any treatment protocol started.
Table 1. Baseline Demographic and Endocrine Data in 74 Healthy Older Men
Variable D/T(2) D/T(+) D/A/E2(2)/T(+) D/A/E2(+)/T(+) ANOVA P
Number of subjects 16 18 20 20
Age (y) 64 6 0.8 66 6 1.0 65 6 1.0 65 6 1.2 0.69
BMI (kg/m2) 28.1 6 1.1 27.7 6 0.8 25.4 6 0.5 26.9 6 0.9 0.12
Visceral fat (cm2) 193 6 25 194 6 22 144 6 13 176 6 23 0.29
HOMA-IR 1.28 6 0.19 1.28 6 0.20 1.00 6 0.15 1.30 6 0.26 0.67
LH (U/L) 5.0 6 0.9 4.0 6 0.4 5.5 6 0.8 4.0 6 0.4 0.23
FSH (U/L) 9.1 6 1.0 6.6 6 0.7 9.9 6 1.3 6.8 6 0.6 0.12
T (ng/dL) 430 6 30 430 6 21 480 6 22 500 6 28 0.11
E2 (pg/mL) 22.6 6 2.5 21.4 6 1.6 27.2 6 1.3 24.7 6 1.3 0.08
SHBG (nmol/L) 45 6 3.3 43 6 3.2 42 6 2.7 50 6 3.3 0.35
TSH (mU/L) 2.33 6 0.2 2.76 6 0.3 2.83 6 0.3 2.90 6 0.3 0.44
PRL (mg/L) 9.2 6 0.9 8.4 6 0.6 8.7 6 0.7 8.3 6 0.6 0.81
Data are shown as the mean 6 SEM. P values were estimated by one-way ANOVA across the four study groups.
Abbreviations: A, anastrozole; D, degarelix; E2(–), no 17b estradiol; E2(+), 17b estradiol; T(2), no testosterone
addback; T(+), testosterone addback.
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Interventions were well tolerated and there were no dropouts. Serum concentrations of IGF-I
and its binding proteins IGFBP3 and IGFBP1 were similar after treatment in the four
groups. Total T and (calculated) free T levels were low in subjects with downregulated go-
nadotropins without T addback, whereas T addback in the other three groups yielded sta-
tistically comparable T concentrations (Table 2). E2 concentrations were lowest in subjects
treated with anastrozole, which inhibits the conversion of T in E2, followed by the control
group with no T addback. Serum SHBG concentrations in E2-depleted men (group C) were
lower than in men with E2 addback (group D); namely, 30.0 6 2.6 and 38.0 6 2.7 nmol/L,
respectively (P = 0.03). Serum prolactin was higher in subjects treated with E2 compared with
men treated with placebo (8.0 6 0.7 mg/L vs 6.2 6 0.3 mg/L, P = 0.02). Furthermore, serum
gonadotropin concentrations were higher in the two groups with low E2 concentrations (post
hoc contrasts for LH and FSH, P, 0.0001), consistent with known negative feedback by E2 on
gonadotropin secretion. However, likely because of differences in sensitivity to degarelix
between individuals, LH and FSH were not completely suppressed in all subjects. This is
obviously important for subjects in group A, whereas the other groups received testosterone
addback. Nevertheless, subjects of group A were all hypogonadal with 80% decrease of free T
levels. Addback of E2 or T or the combination had no influence on serum lipids, including TC,
HDL-C, LDL-C, non-HDL-C, TG, ApoB, and LP(a). Adiponectin and leptin concentrations
were higher in men treated with degarelix only (group A) compared with the other three
groups, who received addback of one or both sex steroids (Table 3). Absolute values of the
inflammatory markers, hsCRP and IL-n-6, were higher in subjects treated with degarelix
only (group A). However, differences with men who received E2 and/or T addback were
not important.
Based upon linear regression analysis, TC, HDL-C, LDL-C, non-HDL-C, TG, ApoB, and
Lp(a) were not related to serum E2 or T concentrations (Table 4). Restricting analysis to
subjects treated with anastrozole (groups C and D), serum E2 and lipid concentrations also
were not correlated (Table 4). On the other hand, CT-estimated abdominal visceral fat area
correlated positively with TG (R = 0.34, P = 0.004), nonsignificantly with non-HDL (R = 0.20,
P = 0.07) and negatively with HDL-C (R = 20.28, P = 0.017). Additionally, visceral fat area
correlated positively with leptin (R = 0.72, P , 0.0001) and hsCRP (R = 0.33, P = 0.005) (Fig.
1). Serum SHBG concentrations were linearly related to Lp(a) (R = 20.30, P = 0.011) and
leptin (R = 0.37, P = 0.001), but nonsignificantly to adiponectin (R = 0.22, P = 0.06).
3. Discussion
This prospectively randomized, placebo-controlled, single-masked study investigated sepa-
rate and combined effects of E2 and T addback in older healthymen under a sex-steroid clamp
Table 2. IGF-I, IGF-Binding Proteins, and Sex Hormones During Hormone Administration in 74
Older Men
Group A Group B Group C Group D ANOVA
IGF-I (mg/L) 106 6 8.4 111 6 7.4 106 6 6.6 114 6 6.1 0.80
IGFBP1 (mg/L) 1.51 6 0.19 1.31 6 0.12 1.40 6 0.15 1.14 6 0.07 0.25
IGFBP3 (mg/L) 2.96 6 0.19 2.84 6 0.12 3.06 6 0.14 2.89 6 0.12 0.68
Estradiol (pg/mL) 9.4 6 1.9a 31.2 6 3.5b 1.21 6 0.24c 82 6 18d <0.0001
Free testosterone (ng/dL) 3.1 6 0.7a 19.5 6 1.9b 19.9 6 2.0b 20.4 6 1.8b <0.0001
Testosterone (ng/dL) 164 6 35a 760 6 61b 748 6 71b 845 6 66b <0.0001
SHBG (nmol/L) 37 6 3.3 33 6 2.9 30 6 2.4 38 6 2.7 0.22
Prolactin (mg /L) 6.5 6 0.6a 10.4 6 0.8b 6.2 6 0.3a 8.0 6 0.7a,b <0.0001
FSH (U/L) 4.0 6 0.9a 0.29 6 0.04b 5.02 6 1.18a 0.33 6 0.06b <0.0001
LH (U/L) 2.4 6 0.5a 0.21 6 0.1b 1.50 6 0.34a 0.24 6 0.09b <0.0001
Data are shown asmean6 SEM. Differing superscripts denote significant post hoc contrasts by multiple-comparison
testing among the four treatment groups. Boldface values denote P , 0.01 level of significance.
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enforced after gonadal-axis downregulation with a potent, selective, and long-acting GnRH
antagonist, degarelix. T was added back in some groups, and its conversion to E2 was
inhibited by the aromatase blocker, anastrozole, in two other groups. Placebo or E2 was then
added back under anastrozole block. Sex-steroid concentrations were quantified by mass
spectrometry, yielding an absolute range of mean E2 concentrations of 1.2 to 82 pg/mL across
the four study groups.
The current study circumvents many earlier issues by experimentally fixing systemic
T concentrations for 22 6 1 days, whereas adjusting serum E2 concentrations over a nearly
80-fold range verified by mass spectrometry to ensure accurate quantification of very low E2
levels. We are unaware of any prior investigations constraining E2 in men over a comparable
range while fixing T concentrations. The short study interval of 3 weeks obviates major shifts
in body composition otherwise observed over more prolonged intervals, although minor
changes may occur short term in severe acute hypogonadism [23]. In the current study, only
group A had reduced testosterone levels, whereas the other three groups had normal levels
under T addback, limiting concerns about a possible (minor) change in body composition.
Under the present conditions, marked E2 variations did not detectably alter LDL-C, HDL-C,
TG, TC, non-HDL-C, Lp(a), ApoB, hsCRP or IL-6 concentrations. In contrast, extensive
Table 3. Lipid Profiles and Inflammatory Markers During Hormone Administration in 74 Older
Healthy Men
Parameter Group A Group B Group C Group D ANOVA
TC (mg/dL) 175 6 7.1 166 6 6.3 158 6 7.1 166 6 5.0 0.34
HDL-C (mg/dL) 42 6 3.5 37 6 2.8 42 6 3.3 42 6 2.6 0.62
LDL-C (mg/dL) 100 6 6.3 91 6 4.3 84 6 5.8 90 6 4.5 0.018a
Non-HDL-C (mg/dL) 133 6 6.7 128 6 6.2 116 6 7.2 124 6 4.9 0.31
Triglycerides (mg/dL) 161 6 16.7 187 6 20.9 163 6 16.9 168 6 19.0 0.77
Lp(a) (mg/dL) 27.0 6 6.3 23.3 6 5.3 21.9 6 4.4 16.8 6 4.1 0.55
ApoB (mg/dL) 0.88 6 0.044 0.84 6 0.043 0.78 6 0.049 0.82 6 0.029 0.34
Adiponectin (mg/dL) 9840 6 1190 6120 6 616 7690 6 650 8250 6 980 0.039b
HsCRP (mg/dL) 0.36 6 020 0.17 6 0.05 0.076 6 0.012 0.11 6 004 0.16
Leptin (ng/mL) 14.6 6 2.1 9.6 6 1.9 6.8 6 0.7 10.2 6 1.9 0.023c
Interleukin 6 (pg/mL) 5.2 6 2.1 3.8 6 0.6 3.4 6 0.4 3.9 6 0.7 0.67
Data are shown as mean 6 SEM. Boldface values denote ANOVA P , 0.05.
Post hoc contrasts:
aGroup A vs group C: P = 0.029.
bGroup A vs groups B, C, D jointly: P = 0.008.
cGroup A vs groups B, and C and D jointly: P = 0.02, group A vs group B; P = 0.005.
Table 4. LinearRegressionsAmongSerumSex-HormoneConcentrations andLipids, Lipoproteins, and
Inflammatory Proteins, and Analogously for Visceral Fat in 74 Older Men
T Free T E2
E2 in Anastrozole-
Treated Subjects Visceral Fat Area
Total cholesterol 20.065/0.58 20.10/0.39 +0.024/0.84 +0.052/0.75 +0.071/0.56
Triglycerides +0.02/0.87 20.00/0.99 +0.09/0.94 +0.023/0.89 +0.34/0.004
HDL-C +0.008/0.95 20.004/0.98 +0.052/0.67 +0.031/0.85 -0.28/0.017
LDL-C 20.088/0.46 20.015/0.31 20.006/0.96 +0.028/0.87 +0.008/0.95
Non-HDL-C 20.062/0.60 20.10/0.39 +0.001/0.99 +0.038/0.82 +0.20/0.07
ApoB +0.07/0.55 20.109/0.36 +0.046/0.70 +0.023/0.89 +0.12/0.32
Lp(a) 20.030/0.80 +0.066/0.58 20.047/0.69 20.045/0.78 +0.002/0.99
hsCRP 20.14/0.23 20.17/0.16 +0.061/0.06 20.051/0.76 +0.33/0.005
Leptin 20.078/0.51 20.22/0.06d +0.036/0.76 +0.010/0.52 +0.72/<0.0001
Adiponectin 20.007/0.95 20.063/0.60 20.004/0.97 +0.020/0.87 20.22/0.06
IL-6 20.15/0.22 20.17/0.15 20.06/0.62 20.078/0.64 +0.17/0.16
Data are the linear correlation coefficient (b) and P value. Boldface values denote that individual data are plotted in
Figure 1.
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available literature establishes that nonaromatizable anabolic steroids and androgenic
progestins consistently suppress HDL, often markedly [24], depending upon chemical
structure, dose, route, and duration of exposure [14, 25].
Estradiol administration for 22 6 1 day in the current study resulted in well-known
stimulatory effects on serum prolactin and SHBG concentrations. This verifies adequacy of
the E2 clamp to modulate known endocrine targets of E2. Furthermore, in the presence of low
E2 and/or low T levels, the competitively antagonistic effect of degarelix on gonadotropin
secretion was partly disinhibited. Thus, expected hypothalamopituitary and hepatic effects of
sex steroids were present in these sex steroid–clamped healthy subjects.
In the overall cohort of 74 men, no effects of either E2 or T on the lipid profile could be
demonstrated, including on TC, HDL-C, LDL-C, non-HDL-C, TG, ApoB, and Lp(a). The
power of these observations was emphasized by the absence of important (linear) re-
lationships between serum T and E2 concentrations on one hand and lipid concentrations on
the other. In women, the beneficial effects of endogenous estrogens including E2 on lipids and
cardiovascular risk are well accepted, inasmuch as premenopausal women are protected from
cardiovascularmortality compared with age-matchedmen. Aftermenopause, a less favorable
lipid profile emerges, along with higher vascular risk. The menopausally defined low es-
trogen, androgen, and progesterone milieu is associated with increased TC, LDL-C, and TG,
but decreased HDL-C and Lp(a) [26]. Administration of estrogens to postmenopausal women
can improve the lipid profile, depending on the choice of estrogen; the dose, duration, and
route of administration; and accompanying progestin [27].
In uncontrolled epidemiological studies, long-term effects of sex-steroid administration
can introduce confounding factors (e.g., changes in lifestyle and/or body composition), which
secondarily alter lipoproteins and inflammatorymarkers. These drawbacks were avoided in a
Figure 1. Linear regressions between abdominal visceral fat area and each of HDL-C, TG,
leptin, or hsCRP in 74 healthy older men. P values are for the indicated slope (b coefficient)
and R (correlation) values.
888 | Journal of the Endocrine Society | doi: 10.1210/js.2018-00141
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/article-abstract/2/8/882/5046520 by Leiden U
niversity / LU
M
C
 user on 15 August 2019
recent placebo-controlled prospective short-term study in postmenopausal women [13]. The
paradigm demonstrated that E2 and natural progesterone modify lipids and inflammatory
markers after 3 weeks of sex-steroid treatment. The current study exploits an analogous sex-
steroid clamp strategy adapted to men, wherein systemic E2 and T concentrations are ex-
perimentally controlled. The absence of estrogenic effects on the lipid profile in this paradigm
in men raises the possibility that lipoproteins are less sensitive to estrogen in men than
women, although mass spectrometry–quantified E2 concentrations were numerically com-
parable inmen (81 pg/mL) and women (99 pg/mL) in the two studies [13]. As positive controls,
there were clear effects of administered E2 on prolactin, SHBG, and gonadotropin concen-
trations in both women and men. Thus, the present clinical model of E2 administration is
sufficient to demonstrate expected E2 regulation of well-known physiological endpoints.
Investigations of the effects of estrogens on lipid concentrations in men are limited by
cohort selection and clinical context (e.g., male-to-female transsexuals and patients with
prostatic carcinoma). In a recent study by Auer et al., 24 previously untreated male-to-female
transgender patients were studied at baseline and after 12 months of oral estrogen exposure.
In response to estrogen, fat mass and the waist:hip ratio decreased, along with TG, TC, and
HDL-C [11]. Another study of E2 administration in men reported increased HDL-C and TG
concentrations after 6 months [4]. Potential interpretational problems in these studies are
concomitant changes in body composition, simultaneous exposure to antiandrogens and/or
antiprogestins, and profound reduction in serum T concentrations. The combined factors do
not allow facile interpretation of direct or exclusive E2 effects on lipid measures and in-
flammatory markers in such individuals.
Inmenwith prostatic carcinoma, orchiectomywithmonthly injections of polyphosphate E2
or daily oral administration of ethinyl E2 decreased TC, LDL-C, and ApoB while increasing
HDL-C [28]. Similar findings occurred during very high-dose transdermal E2 treatment
(0.6 mg/d), which is sixfold the menopausal dose [2]. In these settings, serum E2 concen-
trations were at least fourfold greater than those in our study, whereas total and free T
concentrations were in the hypogonadal or castrate ranges [2]. Some drawbacks of these
studies were circumvented by a study using an early-generation GnRH antagonist along
with parenteral T addback and a relatively nonspecific aromatase inhibitor, testolactone
[29]. In the young men in whom E2 levels decreased, HDL-C decreased by 8%, and apo-
lipoprotein A by 6%. Concentrations of TC, LDL-C, and TG did not change. Unfortunately,
mass spectrometry was not used to quantify T or E2, E2 was not added back, and no data on
ApoB, Lp(a), or cytokine concentrations were reported. Collectively, these heterogeneous
studies in very different populations suggest that, in the face of demonstrably normal adult
male T levels, the effects of nonfeminizing concentrations of E2 on LDL-C, HDL-C, and TG
are limited.
Adiponectin and leptin concentrations were higher in hypogonadal men, defined here by
low serum T, free T, and E2 concentrations after 3 weeks. In chronically hypogonadal men, T
repletion normalized initially elevated leptin levels [30]. Analogously, in healthy men,
treatment with a GnRH-receptor antagonist reduced T levels in 7 days, and increased
adiponectin levels. Concomitant addition of T prevented the rise of adiponectin [31]. Like-
wise, long-term (6 to 12 months) of T treatment in female-to-male transsexual patients
decreased adiponectin [32] as well as leptin [11, 33]. Accordingly, T and/or its metabolites can
diminish leptin and adiponectin concentrations. Because the same cytokines did not decrease
in the current study after anastrozole’s blockade of T-to-E2 conversion, we infer that T’s
restoration of cytokine levels does not depend upon physiological amounts of E2 derived from
T’s aromatization. Indeed, in another study, transdermal E2 administration in men with
prostate cancer for 8 weeks did not alter leptin levels [2]. On the other hand, short-term
aromatase inhibition in young and elderly men resulting in increased T and decreased E2
levels was accompanied by increased leptin, but unchanged adiponectin, concentrations [34].
Although available data do not agree on all points, overall observations on the regulation of
serum leptin and adiponectin in sex-hormone controlled men are compatible with androgen
and not estrogen effects on these adipokines.
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Although in vitro studies have shown a direct negative effect of testosterone and dihy-
drotestosterone on leptin secretion by rodent adipocytes [35], a direct effect on adiponectin
secretion in human adipocytes is not present [36]. Additional investigations have shown that
humoral serum components of high molecular weight are involved in the secretion of various
molecular forms of adiponectin [37].
The inflammatory markers, IL-6 and hsCRP, assessed in this study were not different
among the four groups. In addition, their levels were not related to serum concentrations of
E2, T, and free T, suggesting that they are not modulated short-term by T or E2 availabilities
in men. Comparable conclusions were reached in other studies based upon T administration
in older men, transdermal E2 administration in patients with prostatic carcinoma [2], and
anastrozole administration in elderly men with low T [38].
Limitations of the current analysis include the relatively small cohort (n = 74men), shorter
duration of observation (3 weeks), and absence of more exhaustive lipid fractionation bymass
spectrometry, PAGE or other laboratory techniques, as well as the restricted age range
evaluated. Thus, our outcomes do not necessarily apply to populational data, or reflect ex-
pected outcomes after lipid subfractionation, or in young adult cohorts. Likewise, our study
does not address cardiovascular outcomes per se, which have been reviewed by others re-
cently [8, 39].
In summary, this clinical investigation delineates the absence of influence of a very wide
range of near-physiological concentrations of E2 under fixed T concentrations on lipid
measures and inflammatory markers in older healthy men over 22 days. Acutely induced
central hypogonadism in men is associated with increased metabolic cytokines, adiponectin
and leptin, which are normalized during T addback whether T’s conversion to E2 is blocked.
The last finding indicates that aromatase activity is not required to transduce T’s suppression
of these adipocytokines.
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